Hansa Biopharma AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	676.46	701.08	405.28	732.06	1,496	651.34
Short-Term Investments	-	-	-	-	-	237.62
Cash & Short-Term Investments	676.46	701.08	405.28	732.06	1,496	888.96
Cash Growth	170.37%	72.99%	-44.64%	-51.07%	68.31%	-35.47%
Accounts Receivable	70.16	53.87	26.78	78.03	42.96	9.71
Other Receivables	41.63	18.21	17.49	15.73	24.22	13.53
Receivables	111.8	72.08	44.27	93.76	67.18	23.24
Inventory	6.04	6.13	2.61	1.51	0.97	0.24
Prepaid Expenses	-	3.47	2.84	3.06	3.52	3.34
Other Current Assets	-	13.85	12.24	24.76	36.85	26.56
Total Current Assets	794.3	796.61	467.24	855.15	1,605	942.34
Property, Plant & Equipment	10.67	13.35	17.88	27.07	35.84	41.71
Other Intangible Assets	234.27	17.41	20.46	23.17	26.01	28.76
Long-Term Accounts Receivable	122.96	126.25	118.19	-	-	-
Long-Term Deferred Charges	-	213.15	176.88	112.65	20.85	-
Total Assets	1,162	1,167	800.64	1,018	1,687	1,013
Accounts Payable	54.27	54.06	37.62	86.97	62.48	53.36
Accrued Expenses	91.16	94.23	97.89	116.54	100.32	78.22
Current Portion of Long-Term Debt	-	136.87	-	-	-	-
Current Portion of Leases	6.32	8.28	7.68	7.5	7.17	6.89
Current Income Taxes Payable	2.11	1.83	2.71	1.6	0.6	-
Current Unearned Revenue	-	-	16.33	41.47	40.43	24.96
Other Current Liabilities	64.99	115.4	93.45	66.91	53.71	7.79
Total Current Liabilities	218.84	410.66	255.69	320.99	264.71	171.22
Long-Term Debt	1,133	790.53	1,065	844.9	762.6	-
Long-Term Leases	2.58	3	6.68	14.36	21.33	28.49
Long-Term Unearned Revenue	1.63	1.61	-	-	29.5	47.02
Long-Term Deferred Tax Liabilities	0.25	0.26	0.17	0.37	0.41	0.43
Other Long-Term Liabilities	80.79	49.71	63.3	5.3	5.95	8.08
Total Liabilities	1,437	1,256	1,390	1,186	1,084	255.24
Common Stock	-275.27	101.76	67.81	55.03	55.03	46.34
Additional Paid-In Capital	-	4,457	3,454	3,083	3,022	2,573
Retained Earnings	-	-4,644	-4,110	-3,303	-2,471	-1,860
Treasury Stock	-	-2.03	-2.36	-2.36	-2.59	-1.86
Comprehensive Income & Other	-	-2.03	0.94	-0.41	0.01	0.13
Shareholders' Equity	-275.27	-88.99	-589.83	-167.88	602.91	757.57
Total Liabilities & Equity	1,162	1,167	800.64	1,018	1,687	1,013
Total Debt	1,142	938.67	1,079	866.77	791.09	35.38
Net Cash (Debt)	-465.8	-237.59	-673.73	-134.71	705.09	853.58
Net Cash Growth	-	-	-	-	-17.40%	-37.81%
Net Cash Per Share	-5.19	-2.93	-10.72	-2.56	15.70	19.19
Filing Date Shares Outstanding	101.76	101.76	67.81	52.67	52.44	44.47
Total Common Shares Outstanding	101.76	101.76	67.81	52.67	52.44	44.47
Working Capital	575.46	385.95	211.56	534.16	1,340	771.12
Book Value Per Share	-2.70	-0.87	-8.70	-3.19	11.50	17.03
Tangible Book Value	-509.54	-106.4	-610.29	-191.05	576.9	728.81
Tangible Book Value Per Share	-5.01	-1.05	-9.00	-3.63	11.00	16.39

Source: S&P Global Market Intelligence. Standard template. Financial Sources.